Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
NCT01710202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2015-03-20
Summary
The current study will test the causal relationship between elevated levels of cortisol and the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to environmental threat. The investigators predict that carriers of the short allele of the serotonin transporter gene who have elevated cortisol levels will be most sensitive to threatening environments, whereas carriers of the long allele who do not have elevated cortisol (placebo subjects) will be least sensitive.
Conditions
- Major Depressive Disorder
- Anxiety Disorders
Interventions
- DRUG
-
Hydrocortisone
Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Sponsors & Collaborators
-
University of Texas at Austin
lead OTHER
Principal Investigators
-
Robert A Josephs, Ph.D. · University of Texas at Austin
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2013-12-31
- Completion
- 2014-11-30
Countries
- United States
Study Locations
More Related Trials
-
Treatment of Mild and Subthreshold Depressive Disorders
NCT00226642 ·Status: UNKNOWN ·Phase: PHASE4
-
Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder
NCT06704594 ·Status: RECRUITING ·Phase: PHASE4
-
Treatment of Post-Traumatic Brain Injury (TBI) Depression
NCT00233103 ·Status: COMPLETED ·Phase: PHASE2
-
Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
NCT00048854 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
NCT00633399 ·Status: COMPLETED ·Phase: PHASE2
-
Modulation of Visually Evoked Potentials by an Antidepressant
NCT00263133 ·Status: COMPLETED ·Phase: NA
-
Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems
NCT02504931 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Citalopram on Hostility and CHD Risk
NCT00217828 ·Status: COMPLETED ·Phase: NA
-
Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder
NCT00872131 ·Status: COMPLETED
-
TC-5214 as add-on the Treatment of Major Depressive Disorder
NCT00692445 ·Status: COMPLETED ·Phase: PHASE2
-
Can Additional Drug Therapy Accelerate Response Time to Antidepressants
NCT00221494 ·Status: WITHDRAWN ·Phase: PHASE4
-
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
NCT02922725 ·Status: TERMINATED ·Phase: PHASE4
-
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
NCT00581009 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.
NCT00421369 ·Status: COMPLETED ·Phase: NA
-
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
NCT00608543 ·Status: COMPLETED ·Phase: PHASE4
-
Mood, Serotonin and Social Interaction
NCT02051530 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline
NCT01028482 ·Status: COMPLETED ·Phase: NA
-
Cognitive and Drug Therapy for Drug-Resistant Depression
NCT00000376 ·Status: COMPLETED ·Phase: NA
-
Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion
NCT00090831 ·Status: COMPLETED
-
International Study to Predict Optimised Treatment - in Depression
NCT00693849 ·Status: UNKNOWN ·Phase: PHASE4
-
5-HTP and Creatine for Depression R33 Phase
NCT05895747 ·Status: RECRUITING ·Phase: PHASE2
-
Investigating the Neuropsychological Effects of 5-HT2a Antagonism
NCT07022366 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Stress Disorders
NCT00050804 ·Status: COMPLETED ·Phase: PHASE4
-
Antidepressant Discontinuation in Treatment Resistant Depression
NCT03786614 ·Status: UNKNOWN ·Phase: NA
-
Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder
NCT01488266 ·Status: UNKNOWN ·Phase: NA